Oral hypoglycemic agents commonly used in clinical practice include insulin secretagogues, biguanides, α-glucosidase inhibitors and insulin sensitizers, etc. The details are as follows: 1. Insulin secretagogues: they can be divided into sulfonylureas and non-sulfonylureas. Sulfonylureas, such as gliclazide, can promote insulin secretion, which can lower blood glucose; the adverse reactions include hypoglycemia, nausea, and so on. Non-sulfonylureas, such as Repaglinide, can reduce postprandial blood glucose by stimulating the early phase secretion of insulin; adverse reactions include hypoglycemia and diarrhea. Allergic people are forbidden. 2. Metformin: Metformin hydrochloride tablets are more common in the clinic, which can lower blood glucose by inhibiting hepatic glucose output; adverse reactions include nausea, vomiting, abdominal pain, and so on. Allergy is prohibited. 3. α-glucosidase inhibitors: such as acarbose, etc., such drugs can reduce the body’s absorption of glucose to achieve the effect of lowering glucose; adverse reactions include abdominal distension, gastrointestinal flatulence and so on. Allergic people are prohibited. 4. Insulin sensitizers: such as pioglitazone hydrochloride tablets, etc., such drugs can inhibit the formation of liver glycogen and reduce insulin in the body, and then play a role in lowering sugar; adverse reactions are nausea, vomiting, etc.. Allergies are prohibited. It is recommended that patients choose the appropriate hypoglycemic drugs according to their own situation and the doctor’s advice.